A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome

Natalie Eaton-Fitch; Stanley du Preez; Hélène Cabanas; Donald Staines; Sonya Marshall-Gradisnik

doi:10.1186/s13643-019-1202-6

. 2019 Nov 14;8:279. doi: 10.1186/s13643-019-1202-6

A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome

Natalie Eaton-Fitch ^1,^2,^✉, Stanley du Preez ^1,³, Hélène Cabanas ^1,², Donald Staines ^1,², Sonya Marshall-Gradisnik ^1,²

PMCID: PMC6857215 PMID: 31727160

Abstract

Background

Compromised natural killer (NK) cell cytotoxic function is a well-documented and consistent feature of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Other outcomes evaluated in NK cells of ME/CFS patients, however, remain equivocal. The aim of this study was to conduct a systematic review of the literature regarding NK cell phenotype, receptor expression, cytokine production and cytotoxicity in ME/CFS patients and determine the appropriateness as a model for ME/CFS.

Methods

Medline (EBSCOHost), Scopus, EMBASE and PubMed databases were systematically searched to source relevant papers published between 1994 and March 2018. This review included studies examining NK cells’ features in ME/CFS patients compared with HC following administration of specific inclusion and exclusion criteria. Secondary outcomes included genetic analysis in isolated NK cells or quality of life assessment. Quality assessment was completed using the Downs and Black checklist in addition to The Joanna Briggs Institute checklist.

Results

Seventeen eligible publications were included in this review. All studies were observational case control studies. Of these, 11 investigated NK cell cytotoxicity, 14 investigated NK cell phenotype and receptor profiles, three examined NK cell cytokine production, six investigated NK cell lytic protein levels and four investigated NK cell degranulation. Impaired NK cell cytotoxicity remained the most consistent immunological report across all publications. Other outcomes investigated differed between studies.

Conclusion

A consistent finding among all papers included in this review was impaired NK cell cytotoxicity, suggesting that it is a reliable and appropriate cellular model for continued research in ME/CFS patients. Aberrations in NK cell lytic protein levels were also reported. Although additional research is recommended, current research provides a foundation for subsequent investigations. It is possible that NK cell abnormalities can be used to characterise a subset of ME/CFS due to the heterogeneity of both the illness itself and findings between studies investigating specific features of NK function.

Keywords: Chronic fatigue syndrome, Myalgic encephalomyelitis, Natural killer cells, Cytotoxicity

Background

Myalgic encephalomyelitis (ME), also referred to as chronic fatigue syndrome (CFS), is a clinically defined condition characterised by profound dysregulation of the central nervous system and immune system [1, 2], endocrine dysfunction [3], and impaired cellular energy metabolism and ion transport [4, 5]. The global prevalence of ME/CFS is reported to range from 0.2 to 6.3%; however, this is difficult to accurately determine due to the absence of a diagnostic test [6]. Without a biological marker, diagnosis currently relies on the exclusion of all other possible fatigue-related illnesses and identification of ME/CFS cases using various symptom-based criteria [7–9].

In 1994, the Centers for Disease Control and Prevention published the Fukuda Criteria to evaluate and classify ME/CFS patients and provide a basis for diagnosis [8]. A case of ME/CFS is defined under these criteria by the presence of unexplainable chronic fatigue that is not alleviated by rest. At least four additional concurrent symptoms including sore throat, tender lymph nodes, muscle and/or joint pain, impaired cognition and sleep disturbances are necessary for diagnosis. Revised protocols birthed the Canadian Consensus Criteria (CCC) (2003) and the International Consensus Criteria (ICC) (2011) [7, 9]. Post-exertional neuroimmune exhaustion accompanied by numerous neurological, autonomic and neuroendocrine manifestations are notable elements of these revised definitions necessary to formally diagnose a case of ME/CFS.

The aetiology of ME/CFS remains elusive. The involvement of the immune system is supported by the consistent observation of features representative of a ‘flu-like’ illness in addition to reports of disturbed cytokine profiles [10–13], decreased natural killer (NK) cell activity and reduced T lymphocyte response [1, 5, 14–16]. Decreased NK cell activity is considered the most consistent immunological observation in ME/CFS patients [1, 7, 15–19]. Several studies have reported significantly decreased NK cell function in ME/CFS patients compared with healthy controls (HC) [1, 2, 14, 19–28]. These studies have demonstrated variations in NK cell phenotype and regulatory receptors, significantly reduced cytolytic proteins, impaired mitogen-activated protein kinases (MAPK) phosphorylation, increased expression of degranulation markers and impaired calcium (Ca²⁺) mobilisation.

NK cells are large granular lymphocytes of the innate immune system with natural cytotoxicity against tumour cells and virus-infected cells independent of prior sensitisation and in a non-MHC restricted manner [29]. NK cells have a protective role in various inflammatory conditions through immune cell activation, cytokine production and direct cytotoxicity [29]. In human peripheral blood, NK cell sub-populations are defined by their expression of cell-surface molecules, namely CD56 and CD16, which can distinguish cells into the following subsets: CD56^BrightCD16⁻, CD56^BrightCD16^Dim-, CD56^DimCD16⁻, CD56^DimCD16^Bright, CD56⁻CD16^Bright [30]. CD56^DimCD16^Bright NK cells represent at least 90% of all peripheral NK cells and display significantly higher cytolytic capacity against infected or malignant target cells as this sub-population contains more cytolytic proteins and form more conjugates with target cells [31, 32]. CD56^Bright NK cells are potent cytokine producers. The major cytokines produced include interferon-γ (IFN-γ), tumour necrosis factor-α (TNF-α), granulocyte-macrophage colony-stimulating factor, interleukin (IL)-10 and IL-13 [30].

NK cell function relies on the rise of intracellular Ca²⁺ concentrations [33]. Several steps during cytotoxicity are Ca²⁺-dependent including lytic granule polarisation, immune synapse formation and exocytosis of cytolytic proteins [33]. During NK cell activation, the interaction between NK cells and target cells initiates intracellular signals through the MAPK phosphorylation cascade [34]. Downstream phosphorylation of MAPK is responsible for the polarisation and release of cytotoxic granules, otherwise referred to as degranulation. Degranulation marker CD107a is expressed extracellularly following NK cell activation and is used to detect functional activity of NK cells [35]. NK cell cytotoxicity involves the exocytosis of lytic proteins, predominantly perforin, granzyme A and granzyme B, and concludes with apoptosis of the target cell. Perforin, a membrane-disrupting glycoprotein, creates a pore to facilitate the influx of granzyme proteases [36]. Granzyme B possesses the strongest apoptotic activity owing to its ability to rapidly cleave and activate procaspases, ultimately leading to deoxyribonucleic acid (DNA) fragmentation and subsequent cell death [37]. Conversely, granzyme A is a slow-acting activator of apoptosis [38].

Previous investigators have reported equivocal differences in NK cell phenotype, cytokine production and cytotoxicity. However, it is believed that ME/CFS severity or a subset of disease is associated with specific NK cell sub-populations and functional profiles. Using NK cells as vectors for research and diagnostic approaches for ME/CFS is supported by a growing body of evidence, which will be examined in this review. Specifically, NK cell phenotype, receptor expression, cytokine production and cytotoxicity in ME/CFS will be the focus of this review.

Method

Literature search

This review was performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines. PubMed, Scopus, EMBASE and Medline (EBSCOHost) databases were searched. The following full-text terms were searched: ‘chronic fatigue syndrome’ OR ‘myalgic encephalomyelitis’ OR ‘ME/CFS’ AND natural killer cell*. Medical subject headings (MeSH) terms were used for chronic fatigue syndrome/myalgic encephalomyelitis (including systematic exertion intolerance disease) and natural killer cells. Boolean operators ‘OR’ was used to combine all expressions of cases including abbreviation while ‘AND’ was used to include NK cells in conjunction with ME/CFS in the search. Proximity operators were not used during the literature search. Two literature searches were completed in this systematic review on separate occasions by two authors and using the same method. Reference list checking and citation searching was completed, and no additional papers were selected. Searching for unpublished literature was not performed. The primary search completed by the first author (NEF) was on 31st of May 2018 and the final search concluded by another author was on 21st of August 2018 (by HC). No additional papers were identified in the final search or through alternative search databases such as Griffith University institute library or Google Scholar.

Inclusion and exclusion criteria

This systematic review was designed to include observational studies using quantitative methods to compared NK cell profiles and cytotoxic activity in ME/CFS patients compared with HC. Titles and abstracts were screened according to the following criteria by two authors (NEF and HC): (i) all studies reported on NK cell cytotoxicity, NK cell phenotype or receptor profiles, MAPK phosphorylation, degranulation or lytic proteins in ME/CFS patients compared with HC as their primary outcome; (ii) studies were published between 1994 and 2018 to exclude non-Fukuda-based case definitions; (iii) ME/CFS diagnosis fulfilled either Fukuda, CCC or ICC; (iv) human studies in adults age 18 years and above; (v) free full text publications available through institutional access; and (vi) based upon original research.

Studies were excluded if only one out of the two keywords were present in the title or abstract. Studies were excluded if the ME/CFS cohort was compared with another patient group (e.g. fibromyalgia (FM), multiple sclerosis (MS), chronic fatigue) and not compared with HC. Studies were excluded if pharmacological, exercise or sleep interventions were used. Secondary outcomes evaluated include genetic investigations and quality of life (QoL).

Screening of the articles

All papers obtained from the search were imported to Zotero for storage and subsequent screening. To remove the potential for selection bias, two authors also independently completed the screening of papers. The inclusion and exclusion criteria mentioned above were used for publication selection. After review of abstracts and titles by two authors, full texts were also screened. Publications that met the criteria for inclusion were finally reviewed by another author (SMG) and underwent data collection.

Selection of studies and data extraction

Following screening of titles and abstracts, eligible studies were analysed and the following details were extracted and summarised in Tables 1, 2 and 3: (i) author, (ii) year, (iii) country, (iv) study design, (v) sample type (i.e. ME/CFS or HC), (vi) sample size, (vii) outcome(s) and (viii) statistical results. Two authors independently assessed full-text articles for suitability for inclusion in this review.

Table 1.

Summary of study and participant characteristics

Paper details						Sample size
Author	Year	Study design	Diagnostic criteria	Country	Sample	ME/CFS (female%)[years]	HC (female%)[years]
Brenu et al. [42]	2010	Case Control	Fukuda	Australia	NK cells	10	10
Brenu et al. [2]	2011	Case Control	Fukuda	Australia	NK cells	95 (70.5%) [46.47 ± 11.7]	50 (57.7%) [41.9 ± 9.6]
Brenu et al. [43]	2012	Case Control	Fukuda	Australia	NK cells	65 (75.4%) [47.2 ± 11.5]	21 (66.7%) [45.2 ± 9.3]
Brenu et al. [14]	2013	Case Control	Fukuda	Australia	PBMCs	30 [51.15 ± 1.92]	25 [50.42 ± 1.76]
Curriu et al. [48]	2013	Case Control	Fukuda	Spain	PBMCs	22 (73%) [44]	30 (55%) [38]
Fletcher et al. [45]	2010	Case Control	Fukuda	USA	PBMCs	176 (83%) [44]	230 (86%) [41]
Hardcastle et al. [46]	2015	Case Control	Fukuda	Australia	PBMCs	Severe n = 12 (83%) [41.27 ± 10.05]	18 (72%)[41.94 ± 10.76]
Hardcastle et al. [46]	2015	Case Control	Fukuda	Australia	PBMCs	Moderate n = 12 (67%) [44.73 ± 12.9]	18 (72%)[41.94 ± 10.76]
Hardcastle et al. [46]	2015	Case Control	Fukuda	Australia	PBMCs, NK cells	Severe n = 12 (83.3%) [41.25 ± 2.77]	18 (66.7%) [40.39 ± 2.65]
Hardcastle et al. [46]	2015	Case Control	Fukuda	Australia	PBMCs, NK cells	Moderate n = 15 (73.3%) [45.93 ± 2.96]	18 (66.7%) [40.39 ± 2.65]
Huth et al. [21]	2014	Case Control	Fukuda	Australia	NK cells	29 [48.28 + 2.63]	27 [49.15 + 2.51]
Huth et al. [16]	2016	Case Control	Fukuda	Australia	PBMCs	14 [53.5 ± 2.17]	11 [48.82 ± 3.46]
Maher et al. [20]	2005	Case Control	Fukuda	USA	Whole blood	30 (83.3%) [46 ± 10]	19 [43 ± 10]
Marshall-Gradisnik et al. [44]	2016	Case Control	Fukuda	Australia	NK cells	39 (71.8%) [51.69 ± 2]	30 (56.7%) [47.6 ± 2.39]
Nguyen et al. [49]	2016	Case Control	Fukuda	Australia	PBMCs	17 (82%) [48.68 ± 1.06]	19 (68%) [46.48 ± 1.22]
Nguyen et al. [5]	2017	Case Control	Fukuda	Australia	NK cells	25 (68%) [48.82 ± 9.84]	15 (70.6%) [39.2 ± 12.12]
Rivas et al. [51]	2018	Case Control	CCC	Spain	Whole blood	76 (82.9%) [49.78]	73 (82.2%) [48.71]
Stewart et al. [50]	2003	Case Control	Fukuda	USA	Whole blood	90 (69%) [36.7 ± 7.3]	50 (76%) [35.7 ± 9.2]
Theorell et al. [47]	2017	Case Control	CCC	Sweden, Norway	PBMCs	24 (75%) [44]^a	28 (71%) [44]^a
Theorell et al. [47]	2017	Case Control	CCC	Sweden, Norway	PBMCs	24 (79%) [30]^b	24 (79%) [30]^b

Open in a new tab

ME/CFS myalgic encephalomyelitis/chronic fatigue syndrome, HC healthy control, USA United States of America, NK natural killer, PBMC peripheral blood mononuclear cells

^aLocation: Stockholm

^bLocation: Oslo

Table 2.

Summary of primary outcome results

Author	Year	Assessed	Method	Increased in ME/CFS vs. HC (p value)	Decreased in ME/CFS vs. HC (p value)	No significance
Brenu et al. [42]	2010	NK cell phenotypes	Flow cytometry		CD56^Bright (p < 0.05)	CD56^Dim
Brenu et al. [42]	2010	NK cell cytotoxicity	Flow cytometry		K562% lysis (p < 0.05)
Brenu et al. [2]	2011	NK cell phenotypes	Flow cytometry		CD56^Bright (p < 0.001)	CD56^Dim
Brenu et al. [2]	2011	NK cell cytotoxicity	Flow cytometry		K562% lysis (p < 0.05)
Brenu et al. [43]	2012	NK cell phenotypes	Flow cytometry		CD56^Bright (p = 0.02)^a	CD56^Dim
Brenu et al. [43]	2012	NK cell cytotoxicity	Flow cytometry		K562% lysis (p < 0.05)^a
Brenu et al. [14]	2013	NK cell phenotypes	Flow cytometry			CD56^Bright, CD56^Dim KIR, NKG2D
		NK cell cytotoxicity			K562% (p < 0.05)
		NK cell degranulation		CD107a (p < 0.05)
		NK cell lytic proteins			Granzyme B (p < 0.05)	Perforin, Granzyme A
		NK cell cytokine production		IFN-y (p < 0.05)
Curriu et al. [48]	2013	NK cell phenotypes	Flow cytometry	CD69 (p = 0.0004, p < 0.01)^b NKp46 (p < 0.001), (p = 0.0023)^b	CD57 (p = 0.052) (MFI) CD25CD56^Bright (p = 0.0012) CD25CD56^Dim (p = 0.0494)	CD56^Bright, CD56^Dim CD57 (p = 0.1942)
Curriu et al. [48]	2013	NK cell cytotoxicity	Flow cytometry			K562% lysis
Fletcher et al. [45]	2010	NK cell cytotoxicity	⁵¹Cr release		⁵¹Cr (p < 0.000)
Hardcastle et al. [46]	2015	NK cell phenotype	Flow cytometry	KIR3DL1/DL2 (p < 0.004)^a KIR2DL1 (p = 0.011)^a KIR2DL2/DL3 (0.049)^a KIR2DS4 (0.023)^a CD18⁺CD11c⁻ (p = 0.036) CD18⁺CD2⁻ (p = 0.009) SLAM (p = 0.046)	CD56^BrightNKG2D (p = 0.014) KIR2DL2/DL3 (p = 0.045)^a NKp46 (p = 0.021)
Hardcastle et al. [46]	2015	NK cell lytic proteins	Flow cytometry			Perforin, granzyme A, granzyme B
Huth et al. [21]	2014	NK cell phenotype	Flow cytometry		CD56^BrightCD2⁺CD18⁺ (p < 0.01) CD56^DimCD18⁺CD11a⁺CD11c⁺ (p < 0.05)	CD56^DimCD2⁺CD18⁺ CD18⁺CD11a⁺CD11b⁺CD11c⁺
		NK cell degranulation				CD107a/b
		NK cell lytic proteins			CD56^Dim Granzyme B (p < 0.05)	Granzyme A, Perforin
Huth et al. [16]	2016	NK cell MAPK phosphorylation	Flow cytometry	MEK1/2 (p < 0.05) P38 (p < 0.05)	ERK1/2 (p < 0.05)	MEK1/2 P38
		NK cell cytotoxicity			K562% lysis
		NK cell degranulation				CD107a/b
		NK cell lytic proteins				Perforin, Granzyme A, granzyme B
		NK cell phenotype				CD56^Bright, CD56^Dim
		NK cell cytokines				IFN-γ TNF-α GM-CSF
Maher et al. [20]	2005	NK cell phenotype	Flow cytometry		CD56⁺CD3⁻ (p = 0.04)
		NK cell cytotoxicity	⁵¹Cr release		⁵¹Cr (p = 0.001)
		NK cell lytic proteins	Flow cytometry		Perforin (p = 0.01)
Marshall-Gradisnik et al. [44]	2016	NK cell cytotoxicity	Flow cytometry		K562% lysis (p < 0.05).
Nguyen et al. [49]	2016	NK cell phenotype	Flow cytometry		TRPM3⁺ expression in CD56^Bright (p < 0.05)	TRPM3⁺ expression in CD56^Dim
Nguyen et al. [49]	2016	NK cell Ca²⁺ influx	Flow cytometry		CD56^Bright (p < 0.05)^c
Nguyen et al. [5]	2017	NK cell phenotype	Flow cytometry	CD56^DimTRPM3⁺ (p < 0.01)^c	TRPM3⁺ expression in CD56^Bright (p < 0.05) CD69 (p < 0.05)^c	CD69
		NK cell degranulation				CD107a
		NK cell Ca²⁺ influx		CD56^Bright (p < 0.05)^c		CD56^Dim
		NK cell cytotoxicity		K562% lysis (p < 0.05)^c
Rivas et al. [51]	2018	NK cell phenotype	Flow cytometry	CD69 (p = 0.0011) CD56^Bright (p = 0.0075)	NKG2C (p < 0.0001)
Stewart et al. [50]	2003	NK cell phenotype	Flow cytometry		CD56^BrightCD8⁺ (p = 0.04) CD56^BrightCD8⁻ (p = 0.05)^d
Theorell et al. [47]	2017	NK cell phenotype	Flow cytometry	CD56^Dim HLA-DR (p = 0.002)^d
		NK cell cytotoxicity	⁵¹Cr release			K562% lysis IFN-γ inhibition (p = 0.004, 0.009)^c
		NK cell lytic proteins	Flow cytometry			Perforin, Granzyme A/B
		NK cell cytokines		CD56^Dim IFNγ (p = 0.009)^c
		NK cell degranulation				CD107a

Open in a new tab

ME myalgic encephalomyelitis, CFS chronic fatigue syndrome, HC healthy control, NK natural killer, Ca²⁺ calcium, NS no significance, TNF tumour necrosis factor, IFN interferon, MFI mean fluorescence intensity

^aSignificance dependent on longitudinal data

^bSignificance is NK cell phenotype dependent

^cSignificance reported post pharmacological stimulation

^dSignificance dependent on geographical location

Table 3.

Summary of genotyping secondary outcomes

Author	Year	Assessed	Method	Significance	NS
Brenu et al. [2]	2011	NK cell lytic proteins	qRT-PCR	Granzyme A (p < 0.05) Graznyme K (p < 0.05) IFN-γ (p < 0.05)
Marshall-Gradisnik et al. [44]	2016	NK cell ion channel SNP		TRPC4 (p < 0.05) TRPC2 (p < 0.05) TRPM3 (p < 0.05) TRPM8 (p < 0.05)
Marshall-Gradisnik et al. [44]	2016	AChR receptors		CHRNA3 (p < 0.05) CHRNA2 (p < 0.05) CHRNB4 (p < 0.05) CHRNA5 (p < 0.05) CHRNE (p < 0.05)
Theorell et al. [47]	2017	Perforin (PRF1)	PCR		PRF1

Open in a new tab

NK natural killer, NS no significance, qRT-PCR qualitative reverse transcription polymerase change reaction, SNP single-nucleotide polymorphism, PCR polymerase chain reaction, AChR acetylcholine receptors, TRPC transient receptor potential canonical, TRPM transient receptor potential melastatin

Search strategy validation

The search strategy used in this systematic review was validated by an independent party on Wednesday 10th April 2019. No additional papers were found during validation and no papers were excluded.

Quality assessment

Studies were evaluated for quality and bias (performed by NEF and SDP) using the Joanna Briggs Institute (JBI) Checklist for case controls [39]. Additionally, the Downs and Black checklist was also included for items asking further information pertaining to clear description of outcomes and findings, reported probability outcomes, recruitment details and participant representation of populations [40, 41]. Items 3, 4, 8, 9, 13, 14, 15, 17–19, 23–27 of the Downs and Black checklist were excluded due to their specificity for interventional studies and overlap with the JBI checklist.

Results

A total of 523 papers were identified from Medline (EBSCOhost) (111), Embase (159), PubMed (73) and Scopus (180). Papers were screened according to the aforementioned inclusion and exclusion criteria. Figure 1 summarises the results of the literature search using PRISMA.

Overview of papers

The PRISMA flow diagram including information of papers screened, excluded and included is displayed in Fig. 1. The characteristics and primary outcomes of the 17 papers included in this review are summarised in Tables 1 and 2. All papers in this review were observational case control studies that examined NK cells in ME/CFS patients compared with HC. No potentially relevant papers were excluded from this review dependent on availability. At the end of the search and screening of the papers, authors reported no discrepancies.

Participant and study characteristics

The mean number of participants across all papers was 89. Specifically, the mean number of ME/CFS patients was 48 and 41 for HC.

Six studies used isolated NK cells [2, 5, 21, 42–44], seven used PBMCs [23, 25, 45–49], three used whole blood [20, 50, 51] and one used PBMCs as well as isolated NK cells [17]. Primary outcomes included NK cell cytotoxicity, NK cell immunophenotyping and receptor/channel expression, intracellular lytic protein stores and degranulation. NK cell phenotyping was completed in 11 studies [2, 17, 20, 21, 23, 25, 42, 43, 47, 48, 51]; 11 examined NK cell cytotoxicity [2, 5, 20, 23, 25, 42–45, 47]; five examined NK cell degranulation [5, 21, 23, 25, 47]; six examined NK cell lytic proteins [20, 21, 23, 25, 46, 47]; three examined cytokine production [23, 25, 47]; six examined NK cell receptors and markers [5, 17, 25, 45, 47, 48]; one examined NK cell MAPK phosphorylation [23]; and two examined NK Cell Ca²⁺ influx [5, 49].

Other outcomes included genotyping and polymorphism analysis in addition to QoL scores. Three of the studies reported genotyping analysis [2, 44, 47]; one used the short form 36 health survey (SF-36) [51]; one used the Fatigue Severity Scale (FSS) [17]; two employed Dr. Bell’s Disability Scale [17, 46]; two used the Karnofsky Performance Scale [17, 46]; and one applied the FibroFatigue Scale [17].

Literature reporting NK cell cytotoxic function in ME/CFS patients

Studies that analysed NK cell cytotoxicity are summarised in Table 2. Of these papers, seven reported significant reduction in cytotoxic activity in ME/CFS patients compared with HC [2, 20, 25, 42–45]. Additionally, one study reported decreased inhibition of NK cell cytotoxicity following exposure to 0.1 μM (p = 0.004) and 0.01 μM (p = 0.009) of adrenaline, however did not reach significance [47]. One of these studies analysed NK cell cytotoxicity over 12 months [45]. This paper reported significant reductions in NK cell cytotoxicity in ME/CFS patients compared with HC at 0 month, 6 months and 12 months (p < 0.05). Two of these seven papers used the Chromium (⁵¹Cr) release assay to determine the percentage of NK cell target cell death [20, 45], while the remaining five used flow cytometry [2, 25, 42–44].

Of the 11 publications examining NK cell cytotoxicity, three reported no significant changes after stimulation with a target cell line alone [5, 47, 48] (Table 2); however, methods were not consistent which may not reflect the validity of NK cell cytotoxicity results.

Literature reporting changes in NK cell Immunophenotype

Of the 17 publications included in this review, 14 investigated NK cell phenotypes and receptor expression (Table 2) [2, 5, 17, 20, 21, 23, 25, 42, 43, 47–51]. Four studies reported a significant decrease in CD56^Bright NK cell subset in ME/CFS patients compared with HC [2, 42, 43, 50]. One paper reported a significant reduction in CD56^Bright NK cells after 6 months in the ME/CFS patient group [43]. Stewart et al. reported a significant decrease in CD56^BrightCD8^+/− NK cells [50], while an increase in CD56^Bright NK cells was reported in another paper [51]. Of the 14 papers reporting on NK cell phenotype and surface marker expression, five lacked significance for the CD56^Dim NK cell subset between ME/CFS patients and HC [2, 17, 23, 42, 43], while three reported no significance in CD56^Bright NK cells between groups [23, 25, 48].

One study reported increased MHC Class II receptor HLA-DR on CD56^Dim NK cells [47]. Two studies investigated transient receptor potential (TRP) TRPM (melastatin) 3 channel expression on NK cells, with both reporting a significant decrease in CD56^BrightTRPM3⁺ expression [5, 49], whereas a significant increase was reported for CD56^DimTRPM⁺ in one paper [5]. Note that TRPM3 expression on CD56^Bright NK cells was significant without stimulants, whereas CD56^Dim TRPM3 expression was significant following Pregnenolone sulfate and Ionomycin stimulation [5]. Two papers examined CD2, CD11 and CD18 expression on NK cells [17, 21]. One study reported a significant increase in CD18⁺CD11c⁻ and CD18⁺CD2⁻ NK cells in ME/CFS patients compared with HC [17], while another reported a significant decrease in CD56^BrightCD2⁺CD18⁺ and CD56^DimCD18⁺CD11a⁺CD11c⁺ NK cells [21].

Five papers examined NK cell expression of killer-cell immunoglobulin-like receptors (KIRs), activating receptors or signalling lymphocytic activation molecule (SLAM) receptors [17, 21, 46, 48, 51]. Huth et al. reported no significant differences between ME/CFS patients and HC [21]. Conversely, one paper reported significantly increased SLAM receptors [17] and another reported significant increases in selected KIRs and a decrease in NK receptor group 2 member D (NKG2D) and KIR2DL2/DL3 [46]. One investigation reported significantly increased NKp46 [48], whereas another reported significantly decreased NKp46 [17]. The remaining paper reported a significant decrease in NKG2C in ME/CFS patients compared with HC [51].

Moreover, two papers reported significantly increased expression of activation marker CD69 [48, 51] in ME/CFS patients compared with HC. By contrast, one paper reported significantly decreased CD69 expression in ME/CFS patients compared with HC following pharmacological and target cell stimulation; however, the significance was not reported at baseline [5].

Literature reporting changes in NK cell cytokine production

Three papers examined NK cell-dependent cytokine production in ME/CFS patients compared with HC [23, 25, 47] (Table 2). Two reported significantly increased IFN-γ production [25, 47], while one reported no significant differences in IFN-γ, TNFα and GM-CSF between control and patient groups [23].

Literature reporting changes in NK cell lytic proteins

Six publications examined lytic proteins in NK cells of ME/CFS patients compared with HC [20, 21, 23, 25, 45, 47] (Table 2). A significant reduction in Granzyme B was reported in two papers [21, 25]. One publication reported a significant reduction in perforin [20]. No significant differences were reported in four publications for perforin and granzyme A [21, 23, 25, 45] and three reported no significant changes in Granzyme B [23, 45, 47].

Literature reporting changes in degranulation

Four of the included papers investigated the NK cell degranulation markers CD107a and CD107b [5, 21, 23, 25] (Table 2). One paper reported a significant increase in CD107a [25]. Conversely, three publications lacked significance for these degranulation markers [5, 21, 23].

Literature reporting secondary outcomes

Three of the 17 papers included genotype analysis in ME/CFS patients [2, 44, 47] (Table 3). One study used quantitative reverse transcription polymerase chain reaction (qRT-PCR) to measure gene expression [2]. Brenu et al. reported a significant reduction in mRNA coding for granzyme A, granzyme K, perforin, and IFN-γ. Additionally, one study examined polymorphisms in PRF1, the gene coding perforin, however did not report any significant difference [47]. Lastly, one paper examined 678 single-nucleotide polymorphisms (SNPs) in ME/CFS patients; of these, 11 were associated with TRPC (Canonical) 4, TRPC2, TRPM3 and TRPM8; and 14 SNPs were associated with nicotinic and muscarinic acetylcholine receptors (AChR) [44].

Three papers examined correlation between NK cell features and patient severity or QoL [17, 51, 52]. Hardcastle et al. reported a negative correlation between Dr. Bell’s Disability Scale and the Karnofsky Performance Scale (KPS) with CD56^Dim NK cells with CD18⁺CD11c⁻ in ME/CFS patients [17]. One study used the SF-36 to examine patient severity and QoL in association with NK cell phenotypes [51]. This publication reported a negative trend between fatigue and pain scores with NKG2C expression in ME/CFS patients where this was not observed in HC.

Quality assessment of papers

All papers were assessed for quality and bias by two authors using both the Downs and Black checklist and the JBI checklist for case-control studies (Additional file 1: Table S1). The JBI checklist was used due to its specificity with case-control studies. All 17 papers met the JBI criteria for (i) criteria used for cases and controls; (ii) outcomes assessed in standard, valid and reliable way; and (iii) appropriate statistical analysis was used. All 17 papers met the Downs and Black criteria for (i) aims and objectives clearly described, (ii) main outcomes clearly described, (iii) main findings clearly described, (iv) provides estimates of random variability, (v) studies were without data dredging and (vi) main outcomes measured were accurate. Twelve of the 17 papers met the Downs and Black checklist for actual probability values [5, 17, 20, 25, 45–48, 50, 51]. No papers were representative of the entire population from which they were recruited. One publication commented on recruitment time period [43].

All papers provided an internationally accepted case definition for ME/CFS patients and stated appropriate exclusion criteria. Minimal information was provided for the inclusion of HC for the papers included in this systematic review. All papers, excluding Huth et al. (2014) and Nguyen et al. (2016) [24, 52], appropriately matched HC and ME/CFS participants. No papers commented on controlling for confounding variables.

Discussion

The aim of this systematic review was to summarise and examine the evidence available on NK cells in ME/CFS patients. NK cell cytotoxicity, immunophenotype, degranulation, lytic proteins and cytokine production were analysed. Seventeen studies met the inclusion criteria for this review and demonstrated a consistent loss in NK cell cytotoxicity; however, reports regarding the other mentioned outcomes were inconsistent.

Study characteristics

A significant limitation of 15 of the 17 studies was the use of the Fukuda criteria. In comparison to other definitions such as the CCC and ICC, the Fukuda definition is considered broad and can predispose to the misdiagnosis of ME/CFS as the defining symptoms are not specific or limited to ME/CFS. The release of the Fukuda definition was intended to guide ME/CFS research in adult populations [53]. For this reason, the Fukuda definition is the most widely used definition in ME/CFS research and clinical evaluation of patients. An important feature of the CCC and ICC definitions is the requirement of post-exertional malaise and neuroimmune exhaustion, respectively. A review by Brurberg and colleagues examined case definitions employed by 38 studies and reported that no empirical data indicated that any case definition specifically identified ME/CFS patients as having a neuroimmunological condition [54], suggesting that these revised definitions are not vastly superior to the original Fukuda criteria in discerning cases of ME/CFS. Regardless, all these diagnostic criteria require the exclusion of any active or previous medical conditions that may explain for the presence of symptoms.

A consistent laboratory method was the use of flow cytometry to analyse fluorescence of target proteins on NK cells. Flow cytometry is considered a gold standard technique when measuring cell function, expression of surface markers, cytokine and signalling proteins and discriminating between apoptotic and viable cells. Three papers used the ⁵¹Cr release assay to measure NK cell cytotoxic activity [20, 45, 47]. Comparison studies have shown flow cytometric methods to be more sensitive and obtain higher target cell lysis values than the ⁵¹Cr release assay [55, 56]. However, the use of both flow cytometry and ⁵¹Cr release assay in different papers included in this review yielded consistent results of reduced NK cell cytotoxicity.

Natural killer cells in ME/CFS

The findings generated from investigations into NK cell phenotypes in ME/CFS patients vary. A significant reduction in CD56^Bright NK cell subset was a consistent finding across four of the 11 papers reporting on NK cell phenotype. A recent study included in this systematic review, which consisted of 76 ME/CFS patients defined in accordance with the CCC matched with 73 HC, reported that CD56^Bright NK cell subset was significantly higher in ME/CFS patients [51]. This report is not consistent with earlier reports using low sample sizes that employed the Fukuda criteria. Hence, it emphasises the need for consistent case definitions and similar sample sizes to be used to facilitate comparison and may suggest anomalies in NK cell phenotypic profiles in ME/CFS patients or a subset of patients. For example, reduced CD56^Bright NK cells are often observed in patients with juvenile rheumatoid arthritis [30]. Pridgen et al. reported that NK cell subsets in peripheral blood lacked significant differences to samples from healthy donors; however, synovial fluid of adult rheumatoid arthritis patients almost exclusively contained CD56^Bright NK cells [57]. Thus, any inconsistencies in results presented in this review may be explained by the distribution of NK cells in different tissues or may be representative of a subset of patients. Moreover, a limitation of these studies is that some authors investigated different CD56^BrightCD16⁻ or CD56^BrightCD16^Dim subsets, rendering it difficult to make comparisons or draw conclusions. A review by Poli et al. suggested research techniques be harmonised and both sub-populations be grouped together as CD56^Bright NK cells [30], which is supported by the current review.

The reactivity of NK cells is determined by the balance of activating and inhibitory receptors, including, but not limited to, KIRs and natural cytotoxicity receptors (NCRs). NCRs including NKp46, NKp30 and NKp44 are involved in virally infected and tumour cell elimination [58]. There are ambiguous and limited reports on NK cell receptor expression in ME/CFS patients. An Australian investigation reported decreased NKp46 expression in ME/CFS patients [17], whereas one publication included in this review performed in Swedish and Norwegian populations reported a significant increase in NKp46 expression in patients compared with HC [48]. A repeated investigation by Rivas and colleagues in a Spanish cohort reported lack of significance in NKp46 expression on NK cells of ME/CFS patients compared with HC [51]. The latter, as already mentioned, included a high number of participants all fulfilling the CCC, thereby increasing the statistical power and its ability to conclusively detect notable differences between groups. The disparity in findings may be attributable to the use of different case definitions to identify ME/CFS patients and that these studies were completed in different countries. However, though observations were conflicting, changes in NK cell receptor profiles should not be discredited until additional research is completed.

NKG2C, a KIR activating receptor, was reported significantly reduced in ME/CFS patients compared with HC [51]. Conversely, Theorell and colleagues reported no differences in NKG2C [47]. Both papers recruited a large sample size fulfilling the CCC criteria. The discrepancies in findings may emphasise the immunological heterogeneity of ME/CFS. One paper examining multiple KIRs reported a significant increase in several KIRs [46]. Moreover, Rivas et al. reported that changes in NKG2C NK cell expression along with changes in regulatory T lymphocytes phenotypes had 70% accuracy when identifying cases of ME/CFS. Additional research is recommended on NK cell receptors as unbalanced inhibitory and activating receptors may contribute to impaired NK cell cytotoxicity in a subset of patients.

This systematic review included ten papers that examined NK cell cytotoxicity in ME/CFS patients compared with HC. Seven of these reported a significant decrease in NK cell cytotoxicity in ME/CFS. Brenu et al. was the first to report that NK cell cytotoxicity is consistently reduced over 12 months of illness [43]. The loss of overall NK cell cytotoxic activity is the most reliable report among all outcomes examined in this systematic review. Additionally, another investigation by Masuda and colleagues reported a significant reduction in NK cell cytotoxicity in ME/CFS patients compared with non-ME/CFS fatigued controls [18]. Note that this publication was excluded from this review due to the inclusion of chronic fatigue patients as a comparison group. Collectively, the papers included in this review demonstrate that reduced NK cell cytotoxicity is a useful indicator of immune dysfunction in ME/CFS patients. However, the evidence for why this reduction occurs is limited and requires additional research into possible ME/CFS subsets.

Degranulation is measured by surface expression of CD107a and CD107b [35]. Similar to other areas of NK cell research in ME/CFS patients, there are inconsistent reports of changes in degranulation compared with HC. One paper included in this review reported a significant increase in CD107a after stimulation using K562 cell line [25]. Huth et al. reported an increase in CD107a on CD56^Dim NK cells in ME/CFS patients compared with HC; however, this did not reach significance likely due to the small sample size [23]. An increase in NK cell degranulation in ME/CFS patients may lead to the inability to induce sufficient cytotoxicity resulting in increased activation. Additionally, due to abnormalities in NK cell receptors and MAPK phosphorylation, along with new evidence of impaired Ca²⁺ influx in NK cells, dysregulated cellular pathways may compromise degranulation in ME/CFS patients.

Changes in lytic proteins are not always consistent findings, but anomalies in perforin and granzyme B levels were reported [14, 21, 25]. There are many theories regarding the disparities observed in NK cells. Researchers suggest that it is a consequence of paucities in lytic proteins. Lytic proteins are vital for the immune response due to their involvement in elimination of pathogens as part of immune surveillance [59]. Perforin knockout mice had abnormal immune function and were at increased risk of infection, developing autoimmune diseases and lymphomas [60]. Theorell and colleagues in addition to measuring intracellular lytic proteins, investigated polymorphisms to PRF1 [47]. While most ME/CFS participants were determined to have reduced perforin levels compared with HC, only one participant had the PRF1 p.491 V variant that explained these low levels. Although, the mechanism responsible for reduced perforin in ME/CFS remains unknown, it is still believed to contribute to the loss of NK cell cytotoxicity in these patients.

Impaired phosphorylation of MAP kinases and p38 has been implicated in the pathogenesis of ME/CFS and other chronic inflammatory diseases [61]. MAPK phosphorylation mediates fundamental immunological processes leading to cytokine translation, polarisation of cytolytic granules and release of lytic proteins. Huth et al. reported an increased phosphorylation of MEK1/2 in CD56^Bright NK cells in ME/CFS patients [23], which may explain previously reported increased IFN-γ production [25]. Moreover, one paper included in this review reported decreased inhibition of IFN-γ production compared with HC after in vitro treatment with adrenaline [47], possibly indicating abnormalities in NK cell signalling of ME/CFS patients or impaired receptor function. Moreover, the significant reduction reported in ERK1/2 phosphorylation reported in ME/CFS may be positively correlated with impaired Ca²⁺ mobilisation described in recent publications by Nguyen and colleagues. NK cells are dependent on Ca²⁺ for the recruitment and phosphorylation of MAP kinases in addition to translation of lytic proteins, creation of the immune synapse, polarisation of cytolytic granules and the release of lytic proteins [62, 63].

Recent reports of impaired TRP ion channel function in ME/CFS patients may provide an explanation for immune dysfunction. Two papers included in this review examined TRPM3 channel expression and Ca²⁺ influx in addition to NK cell function [5, 49]. A significant reduction of TRPM3 surface expression was reported on NK cells in ME/CFS patients compared with HC along with a reduction in cytoplasmic Ca²⁺ in response to Ca²⁺ modulators. Moreover, a recent electrophysiology investigation used whole-cell patch clamp techniques to report impaired TRPM3 function in NK cells CFS patients/CFS patients and HC [64]. This paper was not included in this review as other NK cell features were not reported. There is growing evidence to suggest the underlying pathomechanism for ME/CFS involves ion channelopathy. As TRP channels are expressed ubiquitously across multiple organ systems, NK cells may act as a suitable model for other TRPM3 expressing tissues and to explore their functions.

Quality assessment

Quality assessment was mostly consistent among several studies. While all papers were reported as not applicable or unclear for standardisation or reliability measurement of exposure, all publications used similar methods that are considered standard including flow cytometry and ⁵¹Cr release assay. Four of the included publications unfortunately did not provide details for defining their methods to correct for multiple comparisons during statistical analysis [2, 5, 44, 50]. Shortcomings were due to limited information on sources of confounding variables and sources of bias. Although there was no direct mention of controlling for confounding variables, studies attempted to address confounding in the following ways: (i) sex- and age-matching; and (ii) restricting comorbidities including but not limited to hypothyroidism et cetera. Selection bias may be a particular issue with some papers as limited information was provided regarding the recruitment of HC. Additional information should be provided regarding the clinical history of all participants including but not limited to ME/CFS onset, routine medications and comorbidities in addition to relevant medical information of HC. The selection criteria for ME/CFS patients appeared mostly consistent throughout all publications and all adhered to internationally accepted criteria. Conclusions drawn from all publications in this systematic review are consistent in many respects. For example, aberrations in NK cell cytotoxic activity or receptor profiles are significant immunological issues in ME/CFS patients that may compromise their ability to battle infections. Any shortcomings are unlikely to discredit the merit of the findings generated by these studies as they are not considered major limitations. However, it is recommended that for future investigations in this area, information be provided for patient socio-demographics, methods of participant recruitment and justification for the reported sample size.

Conclusion

The aim of this systematic review was to examine the current literature available on NK cell cytotoxicity, cytokine production, lytic protein levels, degranulation and immunophenotypes in ME/CFS patients. Some of the publications included in this review provided evidence to suggest that NK cells may represent an important biological marker for investigating and identifying subsets of ME/CFS patients. NK cell cytotoxicity, and perforin levels to a lesser extent, remained a consistent immunological consequence of ME/CFS to provide a suitable foundation for future research in this area.

Supplementary information

13643_2019_1202_MOESM1_ESM.docx^{(32.9KB, docx)}

Additional file 1. Supplementary Table: The Joanna Briggs Institute Checklist for Case Control Studies and Downs and Black cheklist. Items 3, 4, 5, 8, 9, 13, 14, 15, 17-19, 21, 23-27 of the Downs and Black checklist were removed due to their specificity for intervention studies and overlap with the JBI checklist. Abbreviations: JBI, Joanna Briggs Institute; Y, Yes; N, No; N/A not applicable; U, unclear.

Acknowledgements

Not applicable.

Ethical approval and consent to participate

Not applicable.

Availability of supporting data

No datasets were generated or analysed during this manuscript. Data sharing is not applicable to this systematic review.

Abbreviations

⁵¹Cr: Chromium
AChR: Acetylcholine receptors AChR
Ca²⁺: Calcium
CCC: Canadian Consensus Criteria
CFS: Chronic fatigue syndrome
DNA: Deoxyribonucleic acid
FM: Fibromyalgia
HC: Healthy controls
ICC: International Consensus Criteria
IFN-γ: Interferon gamma
IL: Interleukin
JBI: Joanna Briggs Institute
KIR: Killer-cell immunoglobulin-like receptors
KPS: Karnofsky Performance Scale
MAPK: Mitogen activation protein kinases
ME: Myalgic encephalomyelitis
MS: Multiple sclerosis
NCR: Natural cytotoxicity receptors
NK: Natural killer
NKG2D: NK receptor group 2 member D
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
QoL: Quality of life
qRT-PCR: Qualitative reverse transcription polymerase chain reaction
SF-36: Short Form 36-item Health Survey
SLAM: Signalling lymphocytic activation molecules
SNP: Single-nucleotide polymorphisms
TNF-α: Tumour necrosis factor alpha
TRP: Transient receptor potential
TRPC: TRP canonical
TRPM: TRP melastatin

Authors’ contributions

DS and SMG developed the concept for this systematic review and provided critical input for the review of papers. NEF designed this review, search strategy and performed the primary search, screening of papers, analysis of results, primary quality assessment. HC conducted the secondary publication search for this manuscript. SDP conducted the secondary quality assessment and critically reviewed the drafts of this manuscript. All authors critically reviewed the final version of this manuscript. All authors read and approved the final manuscript.

Authors’ information

Not applicable

Funding

This research was supported by the Stafford Fox Medical Research Foundation, the Mason Foundation, Mr. Douglas Stutt, Blake Beckett Foundation, Alison Hunter Memorial Foundation, the McCusker Charitable Foundation, Buxton Foundation, Mr. and Mrs. Stewart, Henty Community, Henty Lions Club and the Change for ME Charity.

Consent for publication

Consent for publication was obtained from all persons involved in the writing and planning of this manuscript.

Competing interests

The authors declare no conflicts of interest. The lead author affirms that this manuscript is an accurate, honest and transparent account of the study undertaken and reported, with no aspects being omitted and any discrepancies explained. The reporting of this work is compliant with PRISMA guidelines.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Natalie Eaton-Fitch, Phone: +61 7 5678 9283, Email: ncned@griffith.edu.au.

Stanley du Preez, Email: stanley.dupreez@griffithuni.edu.au.

Hélène Cabanas, Email: h.cabanas@griffith.edu.au.

Donald Staines, Email: d.staines@griffith.edu.au.

Sonya Marshall-Gradisnik, Email: s.marshall-gradisink@griffith.edu.au.

Supplementary information

Supplementary information accompanies this paper at 10.1186/s13643-019-1202-6.

References

1.Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol. 1990;28:1403–1410. doi: 10.1128/jcm.28.6.1403-1410.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Brenu EW, van Driel ML, Staines DR, Ashton KJ, Ramos SB, Keane J, et al. Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2011;9:81. doi: 10.1186/1479-5876-9-81. [DOI] [PMC free article] [PubMed] [Google Scholar]
3.Hollingsworth KG, Jones DE, Taylor R, Blamire AM, Newton JL. Impaired cardiovascular response to standing in chronic fatigue syndrome. Eur J Clin Investig. 2010;40:608–615. doi: 10.1111/j.1365-2362.2010.02310.x. [DOI] [PubMed] [Google Scholar]
4.Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med. 2009;2:1. [PMC free article] [PubMed] [Google Scholar]
5.Nguyen T, Johnston S, Clarke L, Smith P, Staines D, Marshall-Gradisnik S. Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels. Clin Exp Immunol. 2017;187:284–293. doi: 10.1111/cei.12882. [DOI] [PMC free article] [PubMed] [Google Scholar]
6.Johnston S, Brenu EW, Staines D, Marshall-Gradisnik S. The prevalence of chronic fatigue syndrome/myalgic encephalomyelitis: a meta-analysis. Clin Epidemiol. 2013;5:105. doi: 10.2147/CLEP.S39876. [DOI] [PMC free article] [PubMed] [Google Scholar]
7.Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med. 2011;270:327–338. doi: 10.1111/j.1365-2796.2011.02428.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994;121:953–959. doi: 10.7326/0003-4819-121-12-199412150-00009. [DOI] [PubMed] [Google Scholar]
9.Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndr. 2003;11:7–115. doi: 10.1300/J092v11n01_02. [DOI] [Google Scholar]
10.ter Wolbeek M, van Doornen LJ, Kavelaars A, van de Putte EM, Schedlowski M, Heijnen CJ. Longitudinal analysis of pro-and anti-inflammatory cytokine production in severely fatigued adolescents. Brain Behav Immun. 2007;21:1063–1074. doi: 10.1016/j.bbi.2007.04.007. [DOI] [PubMed] [Google Scholar]
11.Skowera A, Cleare A, Blair D, Bevis L, Wessely SC, Peakman M. High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. Clin Exp Immunol. 2004;135:294–302. doi: 10.1111/j.1365-2249.2004.02354.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
12.Fletcher MA, Zeng XR, Barnes Z, Levis S, Klimas NG. Plasma cytokines in women with chronic fatigue syndrome. J Transl Med. 2009;7:96. doi: 10.1186/1479-5876-7-96. [DOI] [PMC free article] [PubMed] [Google Scholar]
13.Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, Fletcher MA. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun. 2010;24:1209–1217. doi: 10.1016/j.bbi.2010.04.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Brenu EW, Hardcastle SL, Atkinson GM, van Driel ML, Kreijkamp-Kaspers S, Ashton KJ, et al. Natural killer cells in patients with severe chronic fatigue syndrome. Autoimmun Highlights. 2013;4:69–80. doi: 10.1007/s13317-013-0051-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Caligiuri M, Murray C, Buchwald D, Levine H, Cheney P, Peterson D, et al. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol. 1987;139:3306–3313. [PubMed] [Google Scholar]
16.Huth TK, Brenu EW, Ramos S, Nguyen T, Broadley S, Staines D, et al. Pilot study of natural killer cells in chronic fatigue syndrome/myalgic encephalomyelitis and multiple sclerosis. Scand J Immunol. 2016;83:44–51. doi: 10.1111/sji.12388. [DOI] [PubMed] [Google Scholar]
17.Hardcastle SL, Brenu EW, Johnston S, Nguyen T, Huth T, Wong N, et al. Characterisation of cell functions and receptors in chronic fatigue Syndrome/Myalgic encephalomyelitis (CFS/ME) BMC Immunol. 2015;16:35. doi: 10.1186/s12865-015-0101-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
18.Masuda A, Nozoe S-I, Matsuyama T, Tanaka H. Psychobehavioral and immunological characteristics of adult people with chronic fatigue and patients with chronic fatigue syndrome. Psychosom Med. 1994; [DOI] [PubMed]
19.Whiteside TL, Friberg D. Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Am J Med. 1998;105:27S–34S. doi: 10.1016/S0002-9343(98)00155-7. [DOI] [PubMed] [Google Scholar]
20.Maher KJ, Klimas NG, Fletcher MA. Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin Exp Immunol. 2005;142:505–511. doi: 10.1111/j.1365-2249.2005.02935.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Huth T, Brenu E, Nguyen T, Hardcastle S, Johnston S, Ramos S. Characterization of natural killer cell phenotypes in chronic fatigue syndrome/myalgic encephalomyelitis. J Clin Cell Immunol. 2014;5:2. [Google Scholar]
22.Eaton N, Cabanas H, Balinas C, Klein A, Staines D, Marshall-Gradisnik S. Rituximab impedes natural killer cell function in chronic fatigue Syndrome/Myalgic encephalomyelitis patients: a pilot in vitro investigation. BMC Pharmacol Toxicol. 2018;19:12. doi: 10.1186/s40360-018-0203-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
23.Huth TK, Staines D, Marshall-Gradisnik S. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/− natural killer cells in chronic fatigue Syndrome/Myalgic encephalomyelitis patients. J Transl Med. 2016;14:97. doi: 10.1186/s12967-016-0859-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Hardcastle SL, Brenu E, Johnston S, Nguyen T, Huth T, Kaur M. Analysis of the relationship between immune dysfunction and symptom severity in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) J Clin Cell Immunol. 2014;5:2. [Google Scholar]
25.Brenu EW, Huth TK, Hardcastle SL, Fuller K, Kaur M, Johnston S, et al. Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis. Int Immunol. 2013;26:233–242. doi: 10.1093/intimm/dxt068. [DOI] [PubMed] [Google Scholar]
26.Ogawa M, Nishiura T, Yoshimura M, Horikawa Y, Yoshida H, Okajima Y, et al. Decreased nitric oxide-mediated natural killer cell activation in chronic fatigue syndrome. Eur J Clin Investig. 1998;28:937–943. doi: 10.1046/j.1365-2362.1998.00373.x. [DOI] [PubMed] [Google Scholar]
27.Levine PH, Whiteside TL, Friberg D, Bryant J, Colclough G, Herberman RB. Dysfunction of natural killer activity in a family with chronic fatigue syndrome. Clin Immunol Immunopathol. 1998;88:96–104. doi: 10.1006/clin.1998.4554. [DOI] [PubMed] [Google Scholar]
28.Ojo-Amaize EA, Conley EJ, Peter JB. Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome. Clin Infect Dis. 1994;18:S157–S159. doi: 10.1093/clinids/18.Supplement_1.S157. [DOI] [PubMed] [Google Scholar]
29.Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9:503. doi: 10.1038/ni1582. [DOI] [PubMed] [Google Scholar]
30.Poli A, Michel T, Thérésine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126:458–465. doi: 10.1111/j.1365-2567.2008.03027.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
31.Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633–640. doi: 10.1016/S1471-4906(01)02060-9. [DOI] [PubMed] [Google Scholar]
32.Caligiuri MA. Human natural killer cells. Blood. 2008;112:461–469. doi: 10.1182/blood-2007-09-077438. [DOI] [PMC free article] [PubMed] [Google Scholar]
33.Schwarz EC, Qu B, Hoth M. Calcium, cancer and killing: the role of calcium in killing cancer cells by cytotoxic T lymphocytes and natural killer cells. Biochim Biophys Acta BBA-Mol Cell Res. 1833;2013:1603–1611. doi: 10.1016/j.bbamcr.2012.11.016. [DOI] [PubMed] [Google Scholar]
34.Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9:495. doi: 10.1038/ni1581. [DOI] [PMC free article] [PubMed] [Google Scholar]
35.Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294:15–22. doi: 10.1016/j.jim.2004.08.008. [DOI] [PubMed] [Google Scholar]
36.Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2002;2:735. doi: 10.1038/nri911. [DOI] [PubMed] [Google Scholar]
37.Smyth MJ, Trapani JA. Granzymes: exogenous porteinases that induce target cell apoptosis. Immunol Today. 1995;16:202–206. doi: 10.1016/0167-5699(95)80122-7. [DOI] [PubMed] [Google Scholar]
38.Bovenschen N, Quadir R, van den Berg AL, Brenkman AB, Vandenberghe I, Devreese B, et al. Granzyme K displays highly restricted substrate specificity that only partially overlaps with granzyme a. J Biol Chem. 2009;284:3504–3512. doi: 10.1074/jbc.M806716200. [DOI] [PubMed] [Google Scholar]
39.Martin J. © Joanna Briggs Institute 2017 Critical Appraisal Checklist for Case Series. 2017:7.
40.Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377–384. doi: 10.1136/jech.52.6.377. [DOI] [PMC free article] [PubMed] [Google Scholar]
41.Hooper P, Jutai JW, Strong G, Russell-Minda E. Age-related macular degeneration and low-vision rehabilitation: a systematic review: Centre for Reviews and Dissemination (UK); 2008. [DOI] [PubMed]
42.Brenu EW, Staines DR, Baskurt OK, Ashton KJ, Ramos SB, Christy RM, et al. Immune and hemorheological changes in chronic fatigue syndrome. J Transl Med. 2010;8:1. doi: 10.1186/1479-5876-8-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
43.Brenu EW, van Driel ML, Staines DR, Ashton KJ, Hardcastle SL, Keane J, et al. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2012;10:88. doi: 10.1186/1479-5876-10-88. [DOI] [PMC free article] [PubMed] [Google Scholar]
44.Marshall-Gradisnik S, Huth T, Chacko A, Johnston S, Smith P, Staines D. Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome. Appl Clin Genet. 2016;9:39. doi: 10.2147/TACG.S99405. [DOI] [PMC free article] [PubMed] [Google Scholar]
45.Fletcher MA, Zeng XR, Maher K, Levis S, Hurwitz B, Antoni M, et al. Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26. PLoS One. 2010;5:e10817. doi: 10.1371/journal.pone.0010817. [DOI] [PMC free article] [PubMed] [Google Scholar]
46.Hardcastle SL, Brenu EW, Johnston S, Nguyen T, Huth T, Ramos S, et al. Longitudinal analysis of immune abnormalities in varying severities of chronic fatigue Syndrome/Myalgic encephalomyelitis patients. J Transl Med. 2015;13 10.1186/s12967-015-0653-3. [DOI] [PMC free article] [PubMed]
47.Theorell J, Bileviciute-Ljungar I, Tesi B, Schlums H, Johnsgaard MS, Asadi-Azarbaijani B, et al. Unperturbed cytotoxic lymphocyte phenotype and function in myalgic encephalomyelitis/chronic fatigue syndrome patients. Front Immunol. 2017:8. 10.3389/fimmu.2017.00723. [DOI] [PMC free article] [PubMed]
48.Curriu M, Carrillo J, Massanella M, Rigau J, Alegre J, Puig J, et al. Screening NK-, B- and T-cell phenotype and function in patients suffering from chronic fatigue syndrome. J Transl Med. 2013;11:68. doi: 10.1186/1479-5876-11-68. [DOI] [PMC free article] [PubMed] [Google Scholar]
49.Nguyen T, Staines D, Nilius B, Smith P, Marshall-Gradisnik S. Novel identification and characterisation of transient receptor potential melastatin 3 ion channels on natural killer cells and B lymphocytes: effects on cell signalling in chronic fatigue syndrome/Myalgic encephalomyelitis patients. Biol Res. 2016;49:27. doi: 10.1186/s40659-016-0087-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
50.Stewart CC, Cookfair DL, Hovey KM, Wende KE, Bell DS, Warner CL. Predictive immunophenotypes: disease-related profile in chronic fatigue syndrome. Cytometry B Clin Cytom. 2003;53:26–33. doi: 10.1002/cyto.b.10034. [DOI] [PubMed] [Google Scholar]
51.Rivas JL, Palencia T, Fernández G, García M. Association of T and nK cell phenotype with the diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome (Me/cFs) Front Immunol. 2018;9:1028. doi: 10.3389/fimmu.2018.01028. [DOI] [PMC free article] [PubMed] [Google Scholar]
52.Longitudinal associations of lymphocyte subsets with clinical outcomes in chronic fatigue syndrome: Fatigue. 6, 2 n.d. https://www.tandfonline.com/doi/abs/10.1080/21641846.2018.1426371 (Accessed 24 Aug 2018). [DOI] [PMC free article] [PubMed]
53.Syndrome C on the DC for MEF, Populations B on the H of S, Medicine I of. Current Case Definitions and Diagnostic Criteria, Terminology, and Symptom Constructs and Clusters. National Academies Press (US); 2015.
54.Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review. BMJ Open n.d. https://bmjopen.bmj.com/content/4/2/e003973 (Accessed 9 Dec 2018).
55.Aubry JP, Blaecke A, Lecoanet-Henchoz S, Jeannin P, Herbault N, Caron G, et al. Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry. 1999;37:197–204. doi: 10.1002/(SICI)1097-0320(19991101)37:3<197::AID-CYTO6>3.0.CO;2-L. [DOI] [PubMed] [Google Scholar]
56.Flieger D, Gruber R, Schlimok G, Reiter C, Pantel K, Riethmüller G. A novel non-radioactive cellular cytotoxicity test based on the differential assessment of living and killed target and effector cells. J Immunol Methods. 1995;180:1–13. doi: 10.1016/0022-1759(94)00293-6. [DOI] [PubMed] [Google Scholar]
57.Pridgeon C, Lennon GP, Pazmany L, Thompson RN, Christmas SE, Moots RJ. Natural killer cells in the synovial fluid of rheumatoid arthritis patients exhibit a CD56bright,CD94bright,CD158negative phenotype. Rheumatol Oxf Engl. 2003;42:870–878. doi: 10.1093/rheumatology/keg240. [DOI] [PubMed] [Google Scholar]
58.Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, Moretta L, et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med. 1998;188:953–960. doi: 10.1084/jem.188.5.953. [DOI] [PMC free article] [PubMed] [Google Scholar]
59.van den Broek MF, Hengartner H. The role of perforin in infections and tumour surveillance. Exp Physiol. 2000;85:681–685. doi: 10.1017/S0958067000020972. [DOI] [PubMed] [Google Scholar]
60.Osińska I, Popko K, Demkow U. Perforin: an important player in immune response. Cent-Eur J Immunol. 2014;39:109–115. doi: 10.5114/ceji.2014.42135. [DOI] [PMC free article] [PubMed] [Google Scholar]
61.Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy—from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta. 2005;1754:253–262. doi: 10.1016/j.bbapap.2005.08.017. [DOI] [PubMed] [Google Scholar]
62.Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, et al. Bispecific and Trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther. 2012;11:2674–2684. doi: 10.1158/1535-7163.MCT-12-0692. [DOI] [PMC free article] [PubMed] [Google Scholar]
63.Calcium-dependent plasma membrane binding and cell lysis by perforin are mediated through its C2 domain n.d. http://www.jbc.org/content/280/9/8426.full.html (Accessed 26 July 2018). [DOI] [PubMed]
64.Cabanas H, Muraki K, Eaton N, Balinas C, Staines D, Marshall-Gradisnik S. Loss of transient receptor potential Melastatin 3 ion channel function in natural killer cells from chronic fatigue Syndrome/Myalgic encephalomyelitis patients. Mol Med. 2018;24:44. doi: 10.1186/s10020-018-0046-1. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

13643_2019_1202_MOESM1_ESM.docx^{(32.9KB, docx)}

Data Availability Statement

No datasets were generated or analysed during this manuscript. Data sharing is not applicable to this systematic review.

[CR1] 1.Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol. 1990;28:1403–1410. doi: 10.1128/jcm.28.6.1403-1410.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR2] 2.Brenu EW, van Driel ML, Staines DR, Ashton KJ, Ramos SB, Keane J, et al. Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2011;9:81. doi: 10.1186/1479-5876-9-81. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR3] 3.Hollingsworth KG, Jones DE, Taylor R, Blamire AM, Newton JL. Impaired cardiovascular response to standing in chronic fatigue syndrome. Eur J Clin Investig. 2010;40:608–615. doi: 10.1111/j.1365-2362.2010.02310.x. [DOI] [PubMed] [Google Scholar]

[CR4] 4.Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med. 2009;2:1. [PMC free article] [PubMed] [Google Scholar]

[CR5] 5.Nguyen T, Johnston S, Clarke L, Smith P, Staines D, Marshall-Gradisnik S. Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels. Clin Exp Immunol. 2017;187:284–293. doi: 10.1111/cei.12882. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR6] 6.Johnston S, Brenu EW, Staines D, Marshall-Gradisnik S. The prevalence of chronic fatigue syndrome/myalgic encephalomyelitis: a meta-analysis. Clin Epidemiol. 2013;5:105. doi: 10.2147/CLEP.S39876. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR7] 7.Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med. 2011;270:327–338. doi: 10.1111/j.1365-2796.2011.02428.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR8] 8.Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994;121:953–959. doi: 10.7326/0003-4819-121-12-199412150-00009. [DOI] [PubMed] [Google Scholar]

[CR9] 9.Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndr. 2003;11:7–115. doi: 10.1300/J092v11n01_02. [DOI] [Google Scholar]

[CR10] 10.ter Wolbeek M, van Doornen LJ, Kavelaars A, van de Putte EM, Schedlowski M, Heijnen CJ. Longitudinal analysis of pro-and anti-inflammatory cytokine production in severely fatigued adolescents. Brain Behav Immun. 2007;21:1063–1074. doi: 10.1016/j.bbi.2007.04.007. [DOI] [PubMed] [Google Scholar]

[CR11] 11.Skowera A, Cleare A, Blair D, Bevis L, Wessely SC, Peakman M. High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. Clin Exp Immunol. 2004;135:294–302. doi: 10.1111/j.1365-2249.2004.02354.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR12] 12.Fletcher MA, Zeng XR, Barnes Z, Levis S, Klimas NG. Plasma cytokines in women with chronic fatigue syndrome. J Transl Med. 2009;7:96. doi: 10.1186/1479-5876-7-96. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR13] 13.Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, Fletcher MA. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun. 2010;24:1209–1217. doi: 10.1016/j.bbi.2010.04.012. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR14] 14.Brenu EW, Hardcastle SL, Atkinson GM, van Driel ML, Kreijkamp-Kaspers S, Ashton KJ, et al. Natural killer cells in patients with severe chronic fatigue syndrome. Autoimmun Highlights. 2013;4:69–80. doi: 10.1007/s13317-013-0051-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR15] 15.Caligiuri M, Murray C, Buchwald D, Levine H, Cheney P, Peterson D, et al. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol. 1987;139:3306–3313. [PubMed] [Google Scholar]

[CR16] 16.Huth TK, Brenu EW, Ramos S, Nguyen T, Broadley S, Staines D, et al. Pilot study of natural killer cells in chronic fatigue syndrome/myalgic encephalomyelitis and multiple sclerosis. Scand J Immunol. 2016;83:44–51. doi: 10.1111/sji.12388. [DOI] [PubMed] [Google Scholar]

[CR17] 17.Hardcastle SL, Brenu EW, Johnston S, Nguyen T, Huth T, Wong N, et al. Characterisation of cell functions and receptors in chronic fatigue Syndrome/Myalgic encephalomyelitis (CFS/ME) BMC Immunol. 2015;16:35. doi: 10.1186/s12865-015-0101-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR18] 18.Masuda A, Nozoe S-I, Matsuyama T, Tanaka H. Psychobehavioral and immunological characteristics of adult people with chronic fatigue and patients with chronic fatigue syndrome. Psychosom Med. 1994; [DOI] [PubMed]

[CR19] 19.Whiteside TL, Friberg D. Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Am J Med. 1998;105:27S–34S. doi: 10.1016/S0002-9343(98)00155-7. [DOI] [PubMed] [Google Scholar]

[CR20] 20.Maher KJ, Klimas NG, Fletcher MA. Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin Exp Immunol. 2005;142:505–511. doi: 10.1111/j.1365-2249.2005.02935.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR21] 21.Huth T, Brenu E, Nguyen T, Hardcastle S, Johnston S, Ramos S. Characterization of natural killer cell phenotypes in chronic fatigue syndrome/myalgic encephalomyelitis. J Clin Cell Immunol. 2014;5:2. [Google Scholar]

[CR22] 22.Eaton N, Cabanas H, Balinas C, Klein A, Staines D, Marshall-Gradisnik S. Rituximab impedes natural killer cell function in chronic fatigue Syndrome/Myalgic encephalomyelitis patients: a pilot in vitro investigation. BMC Pharmacol Toxicol. 2018;19:12. doi: 10.1186/s40360-018-0203-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR23] 23.Huth TK, Staines D, Marshall-Gradisnik S. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/− natural killer cells in chronic fatigue Syndrome/Myalgic encephalomyelitis patients. J Transl Med. 2016;14:97. doi: 10.1186/s12967-016-0859-z. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR24] 24.Hardcastle SL, Brenu E, Johnston S, Nguyen T, Huth T, Kaur M. Analysis of the relationship between immune dysfunction and symptom severity in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) J Clin Cell Immunol. 2014;5:2. [Google Scholar]

[CR25] 25.Brenu EW, Huth TK, Hardcastle SL, Fuller K, Kaur M, Johnston S, et al. Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis. Int Immunol. 2013;26:233–242. doi: 10.1093/intimm/dxt068. [DOI] [PubMed] [Google Scholar]

[CR26] 26.Ogawa M, Nishiura T, Yoshimura M, Horikawa Y, Yoshida H, Okajima Y, et al. Decreased nitric oxide-mediated natural killer cell activation in chronic fatigue syndrome. Eur J Clin Investig. 1998;28:937–943. doi: 10.1046/j.1365-2362.1998.00373.x. [DOI] [PubMed] [Google Scholar]

[CR27] 27.Levine PH, Whiteside TL, Friberg D, Bryant J, Colclough G, Herberman RB. Dysfunction of natural killer activity in a family with chronic fatigue syndrome. Clin Immunol Immunopathol. 1998;88:96–104. doi: 10.1006/clin.1998.4554. [DOI] [PubMed] [Google Scholar]

[CR28] 28.Ojo-Amaize EA, Conley EJ, Peter JB. Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome. Clin Infect Dis. 1994;18:S157–S159. doi: 10.1093/clinids/18.Supplement_1.S157. [DOI] [PubMed] [Google Scholar]

[CR29] 29.Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9:503. doi: 10.1038/ni1582. [DOI] [PubMed] [Google Scholar]

[CR30] 30.Poli A, Michel T, Thérésine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126:458–465. doi: 10.1111/j.1365-2567.2008.03027.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR31] 31.Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633–640. doi: 10.1016/S1471-4906(01)02060-9. [DOI] [PubMed] [Google Scholar]

[CR32] 32.Caligiuri MA. Human natural killer cells. Blood. 2008;112:461–469. doi: 10.1182/blood-2007-09-077438. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR33] 33.Schwarz EC, Qu B, Hoth M. Calcium, cancer and killing: the role of calcium in killing cancer cells by cytotoxic T lymphocytes and natural killer cells. Biochim Biophys Acta BBA-Mol Cell Res. 1833;2013:1603–1611. doi: 10.1016/j.bbamcr.2012.11.016. [DOI] [PubMed] [Google Scholar]

[CR34] 34.Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9:495. doi: 10.1038/ni1581. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR35] 35.Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294:15–22. doi: 10.1016/j.jim.2004.08.008. [DOI] [PubMed] [Google Scholar]

[CR36] 36.Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2002;2:735. doi: 10.1038/nri911. [DOI] [PubMed] [Google Scholar]

[CR37] 37.Smyth MJ, Trapani JA. Granzymes: exogenous porteinases that induce target cell apoptosis. Immunol Today. 1995;16:202–206. doi: 10.1016/0167-5699(95)80122-7. [DOI] [PubMed] [Google Scholar]

[CR38] 38.Bovenschen N, Quadir R, van den Berg AL, Brenkman AB, Vandenberghe I, Devreese B, et al. Granzyme K displays highly restricted substrate specificity that only partially overlaps with granzyme a. J Biol Chem. 2009;284:3504–3512. doi: 10.1074/jbc.M806716200. [DOI] [PubMed] [Google Scholar]

[CR39] 39.Martin J. © Joanna Briggs Institute 2017 Critical Appraisal Checklist for Case Series. 2017:7.

[CR40] 40.Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377–384. doi: 10.1136/jech.52.6.377. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR41] 41.Hooper P, Jutai JW, Strong G, Russell-Minda E. Age-related macular degeneration and low-vision rehabilitation: a systematic review: Centre for Reviews and Dissemination (UK); 2008. [DOI] [PubMed]

[CR42] 42.Brenu EW, Staines DR, Baskurt OK, Ashton KJ, Ramos SB, Christy RM, et al. Immune and hemorheological changes in chronic fatigue syndrome. J Transl Med. 2010;8:1. doi: 10.1186/1479-5876-8-1. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR43] 43.Brenu EW, van Driel ML, Staines DR, Ashton KJ, Hardcastle SL, Keane J, et al. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2012;10:88. doi: 10.1186/1479-5876-10-88. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR44] 44.Marshall-Gradisnik S, Huth T, Chacko A, Johnston S, Smith P, Staines D. Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome. Appl Clin Genet. 2016;9:39. doi: 10.2147/TACG.S99405. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR45] 45.Fletcher MA, Zeng XR, Maher K, Levis S, Hurwitz B, Antoni M, et al. Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26. PLoS One. 2010;5:e10817. doi: 10.1371/journal.pone.0010817. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR46] 46.Hardcastle SL, Brenu EW, Johnston S, Nguyen T, Huth T, Ramos S, et al. Longitudinal analysis of immune abnormalities in varying severities of chronic fatigue Syndrome/Myalgic encephalomyelitis patients. J Transl Med. 2015;13 10.1186/s12967-015-0653-3. [DOI] [PMC free article] [PubMed]

[CR47] 47.Theorell J, Bileviciute-Ljungar I, Tesi B, Schlums H, Johnsgaard MS, Asadi-Azarbaijani B, et al. Unperturbed cytotoxic lymphocyte phenotype and function in myalgic encephalomyelitis/chronic fatigue syndrome patients. Front Immunol. 2017:8. 10.3389/fimmu.2017.00723. [DOI] [PMC free article] [PubMed]

[CR48] 48.Curriu M, Carrillo J, Massanella M, Rigau J, Alegre J, Puig J, et al. Screening NK-, B- and T-cell phenotype and function in patients suffering from chronic fatigue syndrome. J Transl Med. 2013;11:68. doi: 10.1186/1479-5876-11-68. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR49] 49.Nguyen T, Staines D, Nilius B, Smith P, Marshall-Gradisnik S. Novel identification and characterisation of transient receptor potential melastatin 3 ion channels on natural killer cells and B lymphocytes: effects on cell signalling in chronic fatigue syndrome/Myalgic encephalomyelitis patients. Biol Res. 2016;49:27. doi: 10.1186/s40659-016-0087-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR50] 50.Stewart CC, Cookfair DL, Hovey KM, Wende KE, Bell DS, Warner CL. Predictive immunophenotypes: disease-related profile in chronic fatigue syndrome. Cytometry B Clin Cytom. 2003;53:26–33. doi: 10.1002/cyto.b.10034. [DOI] [PubMed] [Google Scholar]

[CR51] 51.Rivas JL, Palencia T, Fernández G, García M. Association of T and nK cell phenotype with the diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome (Me/cFs) Front Immunol. 2018;9:1028. doi: 10.3389/fimmu.2018.01028. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR52] 52.Longitudinal associations of lymphocyte subsets with clinical outcomes in chronic fatigue syndrome: Fatigue. 6, 2 n.d. https://www.tandfonline.com/doi/abs/10.1080/21641846.2018.1426371 (Accessed 24 Aug 2018). [DOI] [PMC free article] [PubMed]

[CR53] 53.Syndrome C on the DC for MEF, Populations B on the H of S, Medicine I of. Current Case Definitions and Diagnostic Criteria, Terminology, and Symptom Constructs and Clusters. National Academies Press (US); 2015.

[CR54] 54.Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review. BMJ Open n.d. https://bmjopen.bmj.com/content/4/2/e003973 (Accessed 9 Dec 2018).

[CR55] 55.Aubry JP, Blaecke A, Lecoanet-Henchoz S, Jeannin P, Herbault N, Caron G, et al. Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry. 1999;37:197–204. doi: 10.1002/(SICI)1097-0320(19991101)37:3<197::AID-CYTO6>3.0.CO;2-L. [DOI] [PubMed] [Google Scholar]

[CR56] 56.Flieger D, Gruber R, Schlimok G, Reiter C, Pantel K, Riethmüller G. A novel non-radioactive cellular cytotoxicity test based on the differential assessment of living and killed target and effector cells. J Immunol Methods. 1995;180:1–13. doi: 10.1016/0022-1759(94)00293-6. [DOI] [PubMed] [Google Scholar]

[CR57] 57.Pridgeon C, Lennon GP, Pazmany L, Thompson RN, Christmas SE, Moots RJ. Natural killer cells in the synovial fluid of rheumatoid arthritis patients exhibit a CD56bright,CD94bright,CD158negative phenotype. Rheumatol Oxf Engl. 2003;42:870–878. doi: 10.1093/rheumatology/keg240. [DOI] [PubMed] [Google Scholar]

[CR58] 58.Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, Moretta L, et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med. 1998;188:953–960. doi: 10.1084/jem.188.5.953. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR59] 59.van den Broek MF, Hengartner H. The role of perforin in infections and tumour surveillance. Exp Physiol. 2000;85:681–685. doi: 10.1017/S0958067000020972. [DOI] [PubMed] [Google Scholar]

[CR60] 60.Osińska I, Popko K, Demkow U. Perforin: an important player in immune response. Cent-Eur J Immunol. 2014;39:109–115. doi: 10.5114/ceji.2014.42135. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR61] 61.Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy—from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta. 2005;1754:253–262. doi: 10.1016/j.bbapap.2005.08.017. [DOI] [PubMed] [Google Scholar]

[CR62] 62.Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, et al. Bispecific and Trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther. 2012;11:2674–2684. doi: 10.1158/1535-7163.MCT-12-0692. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR63] 63.Calcium-dependent plasma membrane binding and cell lysis by perforin are mediated through its C2 domain n.d. http://www.jbc.org/content/280/9/8426.full.html (Accessed 26 July 2018). [DOI] [PubMed]

[CR64] 64.Cabanas H, Muraki K, Eaton N, Balinas C, Staines D, Marshall-Gradisnik S. Loss of transient receptor potential Melastatin 3 ion channel function in natural killer cells from chronic fatigue Syndrome/Myalgic encephalomyelitis patients. Mol Med. 2018;24:44. doi: 10.1186/s10020-018-0046-1. [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome

Natalie Eaton-Fitch

Stanley du Preez

Hélène Cabanas

Donald Staines

Sonya Marshall-Gradisnik

Abstract

Background

Methods

Results

Conclusion

Background

Method

Literature search

Inclusion and exclusion criteria

Screening of the articles

Selection of studies and data extraction

Table 1.

Table 2.

Table 3.

Search strategy validation

Quality assessment

Results

Fig. 1.

Overview of papers

Participant and study characteristics

Literature reporting NK cell cytotoxic function in ME/CFS patients

Literature reporting changes in NK cell Immunophenotype

Literature reporting changes in NK cell cytokine production

Literature reporting changes in NK cell lytic proteins

Literature reporting changes in degranulation

Literature reporting secondary outcomes

Quality assessment of papers

Discussion

Study characteristics

Natural killer cells in ME/CFS

Quality assessment

Conclusion

Supplementary information

Acknowledgements

Ethical approval and consent to participate

Availability of supporting data

Abbreviations

Authors’ contributions

Authors’ information

Funding

Consent for publication

Competing interests

Footnotes

Contributor Information

Supplementary information

References

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases